Recent News

First-in-Human Trial of Anti-AXL Antibody-Drug Conjugate in Advanced Lung Cancer

ESMO 2019: First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC

WCLC 2019: Comparison of Screening Methods for Those at Risk of Lung Cancer

WCLC 2019: Blood Biomarker–Based Lung Cancer Screening

ESMO 2019: Combination Immunotherapy Versus Chemotherapy in Advanced Lung Cancer

ASTRO 2019: Adding SBRT to Pembrolizumab in Metastatic Lung Cancer

WCLC 2019: First Results Reported From the National Lung Matrix Trial

WCLC 2019: VIOLET Study Reports Benefits of VATS vs Open Lobectomy

WCLC 2019: Tumor Mutational Burden and Treatment Efficacy With Pembrolizumab

Tepotinib Granted Breakthrough Therapy Designation in Subtype of Metastatic NSCLC

WCLC 2019: LIBRETTO-001 Trial Reveals Antitumor Activity of RET Inhibitor

ASTRO 2019: Characterizing Patterns of Disease Progression in Stage III Lung Cancer

Capmatinib Granted FDA Breakthrough Therapy Designation for MET-Mutated Advanced NSCLC

Quality Care 2019: Why Do Some Patients With Lung Cancer Delay TKI Treatment?

WCLC 2019: 5-Year Overall Survival With Nivolumab From CheckMate Trials

WCLC 2019: Real-World Data on Sequential Therapy for ALK-Positive Lung Cancer

WCLC 2019: Final Data From ALUR Trial of Alectinib in Pretreated Lung Cancer

Quality Care 2019: Out-of-Pocket Costs of Oral Agents and Outcomes in Advanced Lung Cancer

Quality Care 2019: Clinical Trial Enrollment and Survival in Metastatic Lung Cancer

Detecting Brain Metastases in Patients With Lung Cancer: Comparison of Imaging Modalities

EMERGING-CTONG 1103 Trial: Neoadjuvant Erlotinib in EGFR-Mutant Lung Cancer

Entrectinib Approved by FDA for ROS1-Positive NSCLC

Two-Drug Combination Targets Resistance in Cancer

Early Results With Dual Inhibition of VEGFR2 and PD-1 in Advanced Lung Cancer

Can Lower Radiation Doses Reduce Damage to Immune System and Improve Outcomes in NSCLC?

Pemetrexed/Carboplatin/Gefitinib: New Standard of Care for Untreated EGFR-Mutant Lung Cancer?

A Risk Prediction Model For Patients With Lung Nodules

Adjuvant Therapy for Completely Resected Advanced Nonsquamous NSCLC

RET Inhibitor Shows Activity in Select Patients With Lung Cancer in ARROW Trial

FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC

ASCO 2019: Dual EGFR and VEGFR Blockade in Metastatic Lung Cancer

ASCO 2019: Interim Results With Neoadjuvant Atezolizumab in Resectable Lung Cancer

ASCO 2019: Proton Therapy Versus Conventional Photon Therapy in Locally Advanced Cancer

ASCO 2019: Comparing Maintenance Therapies for Nonsquamous Lung Cancer

ASCO 2019: Neoadjuvant Combination Checkpoint Blockade in Early-Stage NSCLC

ASCO 2019: Long-Term Survival With Pembrolizumab for Advanced NSCLC

ASCO 2019: Expanding Traditional Clinical Trial Eligibility in NSCLC

Predicting the Course of Lung Cancer in Situ

Pooled Analysis of Use of Entrectinib in ROS1-Positive Lung Cancer

Lung Cancer Organizations Launch Collaborative Foundation for Lung Cancer Community

ELCC 2019: Does Age Affect Toxicity in Immunotherapy-Treated Patients With NSCLC?

ELCC 2019: Patient-Reported Outcomes With Durvalumab in NSCLC

Can Clinical Use of Capsaicin Slow the Spread of Lung Adenocarcinoma?

ELCC 2019: First-Line Treatment With Osimertinib in Advanced EGFR -Mutant NSCLC

ELCC 2019: Larotrectinib in TRK Fusion–Positive Lung Cancer